Table 1.
Clinical Case Summary Information
| Case # |
Age at Initial NVAMD Diagnosis, Race, Sex, Eye |
Type of Macular Surgery |
Time Between PPV and NVAMD (months) |
BCVA after PPV |
BCVA at NVAMD Diagnosis |
BCVA at 2 years |
# of injections year 1 |
# of injections year 2 |
Follow-up Time on Aflibercept (months) |
CNV Type |
CFT Prior to Aflibercept (µm) |
CFT at 2 years (µm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 81 WF, OD | None | 0.0 | 0.0 | 0.0 | 5.0 | 2.0 | 24 | Type 1 | 268 | 246 | |
| 81 WF, OS | Macular Pucker | 117 | 0.0 | 0.60 | 0.18 | 9.0 | 9.0 | 24 | Type 3 with sub-RPE | 558 | 369 | |
| 2 | 83 WF, OD | Macular Pucker | 8 | 0.18 | 0.54 | 0.30 | 7.0 | 7.0 | 23 | Type 1 | 363 | 336 |
| 3 | 93 WF, OS | Macular Pucker | 13 | 0.18 | 0.40 | 0.10 | 8.0 | 10.0 | 24 | Type 3 with vitelliform | 457 | 395 |
| 4 | 83 WM, OD | Stage 3 Macular Hole | 131 | 0.30 | 2.0 | 2.0 | 9.0 | 5.0 | 24 | Type 3 with sub-RPE | 420 | 195 |
# = number; BCVA = best corrected visual acuity in logMAR; CFT = central foveal thickness; CNV = choroidal neovascularization; F = female; M = male; NVAMD = neovascular age-related macular degeneration; OD = right eye; OS = left eye; PPV = pars plana vitrectomy; RPE = retinal pigment epithelium; W = Caucasian